BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4137 related articles for article (PubMed ID: 6950410)

  • 1. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.
    Vogel CW; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1981 Dec; 78(12):7707-11. PubMed ID: 6950410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
    Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
    Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and function of recombinant cobra venom factor.
    Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
    J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic.
    Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
    Mol Immunol; 1990 Oct; 27(10):957-64. PubMed ID: 2233757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
    Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
    Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
    Parker CJ; White VF; Falk RJ
    Complement; 1986; 3(4):223-35. PubMed ID: 3643079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant cobra venom factor.
    Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
    Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells.
    Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
    Immunobiology; 1997 Nov; 197(5):444-59. PubMed ID: 9413745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
    Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
    Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
    Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
    Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C3 convertase of the human alternative pathway of complement: modulation of enzyme activity and stability by mouse monoclonal antibodies to Bb.
    Fishelson Z; Müller-Eberhard HJ
    Eur J Immunol; 1987 Feb; 17(2):303-4. PubMed ID: 3644748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal anti-human C3d antibodies: stabilization of the alternative pathway C3 convertase.
    Tanuma Y; Ohi H; Hatano M
    Immunology; 1989 Dec; 68(4):445-8. PubMed ID: 2532618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent conjugates of monoclonal antibody and cobra venom factor mediate specific cytotoxicity via alternative pathway of human complement activation.
    Müller B; Müller-Ruchholtz W
    Leuk Res; 1987; 11(5):461-8. PubMed ID: 3573809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb.
    Krishnan V; Ponnuraj K; Xu Y; Macon K; Volanakis JE; Narayana SV
    Structure; 2009 Apr; 17(4):611-9. PubMed ID: 19368894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement fixation in acute serum sickness: assembly of glomerular-bound C3-convertase.
    Bartolotti SR; Peters DK
    Clin Exp Immunol; 1979 Sep; 37(3):391-8. PubMed ID: 389495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement.
    Smith CA; Vogel CW; Müller-Eberhard HJ
    J Biol Chem; 1982 Sep; 257(17):9879-82. PubMed ID: 6921201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cobra venom factor (CVF)-induced C3 convertase activity in the hemolymph of Galleria mellonella.
    Phipps D; Menger M; Chadwick JS; Aston WP
    Dev Comp Immunol; 1987; 11(1):37-46. PubMed ID: 3647909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b.
    Reiter Y; Fishelson Z
    J Immunol; 1989 Apr; 142(8):2771-7. PubMed ID: 2522969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methionine modification impairs the C5-cleavage function of cobra venom factor-dependent C3/C5 convertase.
    Fu Q; McPhie P; Gowda DC
    Biochem Mol Biol Int; 1998 Jun; 45(1):133-44. PubMed ID: 9635137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 207.